PURPOSE: Impaired microvascular perfusion in sepsis is not treated effectively because its mechanism is unknown. Since inflammatory and coagulation pathways cross-activate, we tested if stoppage of blood flow in septic capillaries is due to oxidant-dependent adhesion of platelets in these microvessels. METHODS: Sepsis was induced in wild type, eNOS(-/-), iNOS(-/-), and gp91phox(-/-) mice (n = 14-199) by injection of feces into the peritoneum. Platelet adhesion, fibrin deposition, and blood flow stoppage in capillaries of hindlimb skeletal muscle were assessed by intravital microscopy. Prophylactic treatments at the onset of sepsis were intravenous injection of platelet-depleting antibody, P-selectin blocking antibody, ascorbate, or antithrombin. Therapeutic treatments (delayed until 6 h) were injection of ascorbate or the glycoprotein IIb/IIIa inhibitor eptifibatide, or local superfusion of the muscle with NOS cofactor tetrahydrobiopterin or NO donor S-nitroso-N-acetylpenicillamine (SNAP). RESULTS: Sepsis at 6-7 h markedly increased the number of stopped-flow capillaries and the occurrence of platelet adhesion and fibrin deposition in these capillaries. Platelet depletion, iNOS and gp91phox deficiencies, P-selectin blockade, antithrombin, or prophylactic ascorbate prevented, whereas delayed ascorbate, eptifibatide, tetrahydrobiopterin, or SNAP reversed, septic platelet adhesion and/or flow stoppage. The reversals by ascorbate and tetrahydrobiopterin were absent in eNOS(-/-) mice. Platelet adhesion predicted 90% of capillary flow stoppage. CONCLUSION: Impaired perfusion and/or platelet adhesion in septic capillaries requires NADPH oxidase, iNOS, P-selectin, and activated coagulation, and is inhibited by intravenous administration of ascorbate and by local superfusion of tetrahydrobiopterin and NO. Reversal of flow stoppage by ascorbate and tetrahydrobiopterin may depend on local eNOS-derived NO which dislodges platelets from the capillary wall.
PURPOSE: Impaired microvascular perfusion in sepsis is not treated effectively because its mechanism is unknown. Since inflammatory and coagulation pathways cross-activate, we tested if stoppage of blood flow in septic capillaries is due to oxidant-dependent adhesion of platelets in these microvessels. METHODS:Sepsis was induced in wild type, eNOS(-/-), iNOS(-/-), and gp91phox(-/-) mice (n = 14-199) by injection of feces into the peritoneum. Platelet adhesion, fibrin deposition, and blood flow stoppage in capillaries of hindlimb skeletal muscle were assessed by intravital microscopy. Prophylactic treatments at the onset of sepsis were intravenous injection of platelet-depleting antibody, P-selectin blocking antibody, ascorbate, or antithrombin. Therapeutic treatments (delayed until 6 h) were injection of ascorbate or the glycoprotein IIb/IIIa inhibitor eptifibatide, or local superfusion of the muscle with NOS cofactor tetrahydrobiopterin or NO donorS-nitroso-N-acetylpenicillamine (SNAP). RESULTS:Sepsis at 6-7 h markedly increased the number of stopped-flow capillaries and the occurrence of platelet adhesion and fibrin deposition in these capillaries. Platelet depletion, iNOS and gp91phox deficiencies, P-selectin blockade, antithrombin, or prophylactic ascorbate prevented, whereas delayed ascorbate, eptifibatide, tetrahydrobiopterin, or SNAP reversed, septic platelet adhesion and/or flow stoppage. The reversals by ascorbate and tetrahydrobiopterin were absent in eNOS(-/-) mice. Platelet adhesion predicted 90% of capillary flow stoppage. CONCLUSION: Impaired perfusion and/or platelet adhesion in septic capillaries requires NADPH oxidase, iNOS, P-selectin, and activated coagulation, and is inhibited by intravenous administration of ascorbate and by local superfusion of tetrahydrobiopterin and NO. Reversal of flow stoppage by ascorbate and tetrahydrobiopterin may depend on local eNOS-derived NO which dislodges platelets from the capillary wall.
Authors: Stephen R Clark; Adrienne C Ma; Samantha A Tavener; Braedon McDonald; Zahra Goodarzi; Margaret M Kelly; Kamala D Patel; Subhadeep Chakrabarti; Erin McAvoy; Gary D Sinclair; Elizabeth M Keys; Emma Allen-Vercoe; Rebekah Devinney; Christopher J Doig; Francis H Y Green; Paul Kubes Journal: Nat Med Date: 2007-03-25 Impact factor: 53.440
Authors: Kari Otterdal; Camilla Smith; Erik Oie; Turid M Pedersen; Arne Yndestad; Espen Stang; Knut Endresen; Nils O Solum; Pål Aukrust; Jan K Damås Journal: Blood Date: 2006-08-01 Impact factor: 22.113
Authors: Alexander V Ovechkin; David Lominadze; Kara C Sedoris; Tonya W Robinson; Suresh C Tyagi; Andrew M Roberts Journal: Arch Physiol Biochem Date: 2007-02 Impact factor: 4.076
Authors: Scarlett Gillespie; Paul M Holloway; Felix Becker; Francesca Rauzi; Shantel A Vital; Kirk A Taylor; Karen Y Stokes; Michael Emerson; Felicity N E Gavins Journal: Br J Pharmacol Date: 2018-07-03 Impact factor: 8.739
Authors: Anju Mary Philip; Youdong Wang; Antonio Mauro; Suzan El-Rass; John C Marshall; Warren L Lee; Arthur S Slutsky; Claudia C dosSantos; Xiao-Yan Wen Journal: Mol Med Date: 2017-06-07 Impact factor: 6.354
Authors: Roberto Alberto De Blasi; Patrizia Cardelli; Alessandro Costante; Micol Sandri; Marco Mercieri; Roberto Arcioni Journal: Intensive Care Med Date: 2012-10-24 Impact factor: 17.440
Authors: Melissa M Lee; Mehrab Nasirikenari; Charles T Manhardt; David J Ashline; Andrew J Hanneman; Vernon N Reinhold; Joseph T Y Lau Journal: J Biol Chem Date: 2014-02-18 Impact factor: 5.157
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2011-01-04 Impact factor: 17.440